Renaissance Capital logo

Checkmate Pharmaceuticals Priced, Nasdaq: CMPI

Clinical stage immuno-oncology biotech developing therapies for solid tumors.

Industry: Health Care

Latest Trade: $10.50 0.00 (0.0%)

First Day Return: -6.7%

Return from IPO: -30.0%

Industry: Health Care

We are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer. Our product candidate, CMP-001, is a differentiated Toll-like receptor 9, or TLR9, agonist delivered as a biologic virus-like particle, or VLP, utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. In a clinical trial of CMP-001 in combination with a systemic checkpoint inhibitor, or CPI, in patients whose tumors were unresponsive or no longer responsive to a CPI, we have observed a best overall response rate of 28%, including post-progression responders. We have assembled a strong management team and infrastructure to evaluate CMP-001 across multiple tumor types in combination with other immunotherapy agents. Our goal is to establish CMP-001 as a foundational immuno-oncology therapy that engages the innate immune system to fight cancer and improve outcomes for patients with a broad range of solid tumors.
more less
IPO News for Checkmate Pharmaceuticals
more
IPO Data
IPO File Date 07/17/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/06/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2015
Employees 22
Website www.checkmatepharma.com